BMO Capital Remains a Hold on Becton Dickinson


BMO Capital analyst Joanne Wuensch reiterated a Hold rating on Becton Dickinson (NYSE: BDX) on July 10 and set a price target of $262. The company’s shares closed yesterday at $244.63, close to its 52-week high of $248.39.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 10.8% and a 68.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Becton Dickinson is a Moderate Buy with an average price target of $275.

See today’s analyst top recommended stocks >>

The company has a one-year high of $248.39 and a one-year low of $191.53. Currently, Becton Dickinson has an average volume of 1.14M.

Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BDX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts